title: Phosphorylated eIF2α predicts disease-free survival in triple-negative breast cancer patients.
abstract: Phosphorylated eukaryotic translation initiation factor 2α (p-eIF2α), which functions as a marker of endoplasmic reticulum stress, has been reported to be associated with patient prognosis in various cancers. However, little is known about the prognostic value of p-eIF2α in breast cancer, particularly in different breast cancer subtypes. An immunohistochemistry screen for p-eIF2α was performed using a tissue microarray containing 233 tumors and paired peritumoral tissues from female patients diagnosed with breast cancer. The staining results were scored semiquantitatively, and the p-eIF2α expression level in breast cancer and its potential prognostic value were investigated. In this retrospective cohort study, we found that p-eIF2α levels were significantly upregulated in breast cancer (P < 0.001). p-eIF2α level was negatively correlated with lymph node status (P = 0.039). Survival analysis by Kaplan-Meier estimation and Cox regression showed that p-eIF2α level was correlated with better disease free survival (P = 0.026) and served as an independent prognostic factor (P = 0.046) in patients with triple-negative breast cancer. Our study revealed that p-eIF2α was upregulated in breast cancer and represented a novel predictor of prognosis in patients with triple-negative subtype.
authors.affiliation: Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
authors.forename: Liang
authors.initials: L
authors.lastname: Guo
authors.affiliation: Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
authors.forename: Yayun
authors.initials: Y
authors.lastname: Chi
authors.affiliation: Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
authors.forename: Jingyan
authors.initials: J
authors.lastname: Xue
authors.affiliation: Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
authors.forename: Linxiaoxi
authors.initials: L
authors.lastname: Ma
authors.affiliation: Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.
authors.forename: Zhiming
authors.initials: Z
authors.lastname: Shao
authors.affiliation: Department of Breast Surgery, Key Laboratory of Breast Cancer in Shanghai, Fudan University Shanghai Cancer Center, Shanghai 200032, PR China.|Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, PR China.|Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China.
authors.forename: Jiong
authors.initials: J
authors.lastname: Wu
mesh_terms: D000328:Adult; D000368:Aged; D018572:Disease-Free Survival; D015852:Eukaryotic Initiation Factor-2 / Q000235:genetics*; D005260:Female; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008207:Lymphatic Metastasis / Q000235:genetics* / Q000473:pathology; D008875:Middle Aged; D010766:Phosphorylation; D011379:Prognosis; D064726:Triple Negative Breast Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000473:pathology
chemical_list: D015852:Eukaryotic Initiation Factor-2